Effect of Teriflunomide (Aubagio) on Gray Matter Pathology in Multiple Sclerosis: The 12 Months, Prospective, Observational, Single-blinded, Longitudinal Study

Trial Profile

Effect of Teriflunomide (Aubagio) on Gray Matter Pathology in Multiple Sclerosis: The 12 Months, Prospective, Observational, Single-blinded, Longitudinal Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Acronyms GZA
  • Most Recent Events

    • 17 Sep 2016 Results assessing relationship between gray matter atrophy and humaral response to Epstein-Barr virus presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 11 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top